Who are the decision-makers at Adaptive Phage Therapeutics, Inc?

Fundz holds 1 contact at Adaptive Phage Therapeutics, Inc., including the Executive Officer. Names and contact details are shown to Fundz members.

Adaptive Phage Therapeutics Announces $40.75 Million Series B Financing

PRIVATEMay 11, 2021

Amount Raised

$40.8 Million

Round Type

Series B

GaithersburgBiotechnologyHealthcare

Description

Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, today announced that the company has closed a $40.75 million Series B investment round led by Deerfield Management Company. Also joining the Series B round are existing investor Mayo Clinic and an additional undisclosed institutional investor. Proceeds of this financing will be used to accelerate clinical development of PhageBankTM phage therapies, as well as for general corporate purposes.

Quick answer

Adaptive Phage Therapeutics, Inc. raised $40.8 Million in a Series B round, dated May 11, 2021. Adaptive Phage Therapeutics, Inc. is based in Gaithersburg, Maryland, United States.

How much did Adaptive Phage Therapeutics, Inc. raise?: Adaptive Phage Therapeutics, Inc. raised $40.8 Million in a Series B round on May 11, 2021.
What does Adaptive Phage Therapeutics, Inc. do?: Adaptive Phage Therapeutics (APT) is a clinical-stage company advancing therapies addressing multi-drug resistant infections.
Where is Adaptive Phage Therapeutics, Inc. based and how big is it?: Adaptive Phage Therapeutics, Inc. is based in Gaithersburg, Maryland, United States.
Who are the decision-makers at Adaptive Phage Therapeutics, Inc?: Fundz holds 1 contact at Adaptive Phage Therapeutics, Inc., including the Executive Officer. Names and contact details are shown to Fundz members.

Source: Fundz verified event record.

Who else raised in Healthcare and Biotechnology around the same time

Companies in the same sectors as Adaptive Phage Therapeutics, Inc. that raised within 45 days of this round, from Fundz verified event records.

NeuSpera Medical raised $66M on June 24, 2021.
Vita Therapeutics, Inc. raised $32M (Series A) on June 23, 2021.
Arbutus raised $81M on June 23, 2021.
Zevra Therapeutics, Inc. raised $39M on June 22, 2021.
Fractyl Health raised $100M on June 22, 2021.
Greenbrook TMS raised $24M on June 21, 2021.

Who to call at Adaptive Phage Therapeutics, Inc., and when

A new round usually means Adaptive Phage Therapeutics, Inc. is about to hire and buy. The teams that reach out first get the meeting.

An alert the day Adaptive Phage Therapeutics, Inc. raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Adaptive Phage Therapeutics, Inc., from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Adaptive Phage Therapeutics, Inc.. With Fundz connected, it knows.

Watch Fundz in

See plan options

Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Adaptive Phage Therapeutics, Inc.

Location

708 Quince Orchard Road

Gaithersburg, Maryland, United States

About

Adaptive Phage Therapeutics (APT) is a clinical-stage company advancing therapies addressing multi-drug resistant infections. Prior antimicrobial therapeutic approaches have been “fixed,” while pathogens continue to evolve resistance to each of those therapeutics, causing those drug products to become rapidly less effective in commercial use as antimicrobial resistance (AMR) increases over time. APT’s PhageBank™ approach leverages an ever-expanding library of bacteriophage (phage) that collectively provide evergreen broad spectrum and polymicrobial coverage. PhageBank™ phages are matched through a proprietary phage susceptibility assay that APT has teamed with Mayo Clinic Laboratories to commercialize on a global scale. APT’s technology was originally developed by the biodefense program of U.S. Department of Defense. APT acquired the world-wide exclusive commercial rights in 2017. Under FDA emergency Investigational New Drug allowance, APT has provided investigational PhageBank™ therapy to treat more than 40 critically ill patients in which standard-of-care antibiotics had failed.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Adaptive Phage Therapeutics, Inc. raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Book a demo Explore plans

Related People

1 contact

Verified contactsSubhendu B., Executive Officer hiddenSee plans and pricing

Predictive Intelligence

Strategic

ML-powered predictions for Adaptive Phage Therapeutics, Inc.'s next move

See what Strategic adds

Funding Insights

What this usually means

Timeline to next round

Series B companies typically work for 15-20 months before raising new capital

Growth expectations

Series B companies are expected to scale rapidly and expand market reach

Adaptive Phage Therapeutics, Inc. raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

Show me how a sales rep uses this Or see plans and pricing →

5 screens from a live account. No signup.